Herrera, F. G., Bourhis, J. & Coukos, G. Radiotherapy mixture alternatives leveraging immunity for the following oncology follow. CA Most cancers J. Clin. 67, 65–85 (2017).
Demaria, S., Golden, E. B. & Formenti, S. C. Function of native radiation remedy in most cancers immunotherapy. JAMA Oncol. 1, 1325–1332 (2015).
McLaughlin, M. et al. Inflammatory microenvironment remodelling by tumour cells after radiotherapy. Nat. Rev. Most cancers 20, 203–217 (2020).
Barker, H. E., Paget, J. T., Khan, A. A. & Harrington, Ok. J. The tumour microenvironment after radiotherapy: mechanisms of resistance and recurrence. Nat. Rev. Most cancers 15, 409–425 (2015).
Merad, M. & Salmon, H. Most cancers: a dendritic-cell brake on antitumour immunity. Nature 523, 294–295 (2015).
Chen, D. S. & Mellman, I. Oncology meets immunology: the cancer-immunity cycle. Immunity 39, 1–10 (2013).
Tang, M. et al. Toll-like receptor 2 activation promotes tumor dendritic cell dysfunction by regulating IL-6 and IL-10 receptor signaling. Cell Rep. 13, 2851–2864 (2015).
Saxena, M., van der Burg, S. H., Melief, C. J. & Bhardwaj, N. Therapeutic most cancers vaccines. Nat. Rev. Most cancers 21, 360–378 (2021).
Wculek, S. Ok. et al. Dendritic cells in most cancers immunology and immunotherapy. Nat. Rev. Immunol. 20, 7–24 (2020).
Broz, M. L. et al. Dissecting the tumor myeloid compartment reveals uncommon activating antigen-presenting cells important for T cell immunity. Most cancers Cell 26, 638–652 (2014).
Min, Y. et al. Antigen-capturing nanoparticles enhance the abscopal impact and most cancers immunotherapy. Nat. Nanotechnol. 12, 877–882 (2017).
Wang, W. et al. Systemic immune responses to irradiated tumours through the transport of antigens to the tumour periphery by injected flagellate micro organism. Nat. Biomed. Eng. 6, 44–53 (2022).
Teitz-Tennenbaum, S. et al. Radiotherapy potentiates the therapeutic efficacy of intratumoral dendritic cell administration. Most cancers Res. 63, 8466–8475 (2003).
Choi, C. W. et al. Mixture therapy of stereotactic physique radiation remedy and immature dendritic cell vaccination for augmentation of native and systemic results. Most cancers. Res. Deal with. 51, 464–473 (2019).
Baharom, F. et al. Systemic vaccination induces CD8+ T cells and remodels the tumor microenvironment. Cell. 185, 4317–4332.e15 (2022).
Giles, J. R. et al. CD8 T cells within the cancer-immunity cycle. Immunity 56, 2231–2253 (2023).
Verdijk, P. et al. Restricted quantities of dendritic cells migrate into the T cell space of lymph nodes however have excessive immune activating potential in melanoma sufferers. Clin. Most cancers Res. 15, 2531–2540 (2009).
Buzas, E. I. The roles of extracellular vesicles within the immune system. Nat. Rev. Immunol. 23, 236–250 (2023).
Ding, X. et al. Non-discriminating engineered masking of immuno-evasive ligands on tumour-derived extracellular vesicles enhances tumour vaccination outcomes. Nat. Nanotechnol. 20, 156–166 (2024).
Liu, G. et al. Micro organism-derived nanovesicles improve tumour vaccination by educated immunity. Nat. Nanotechnol. 19, 387–398 (2024).
Kalluri, R. & LeBleu, V. S. The biology, operate, and biomedical purposes of exosomes. Science 367, eaau6977 (2020).
Marar, C., Starich, B. & Wirtz, D. Extracellular vesicles in immunomodulation and tumor development. Nat. Immunol. 22, 560–570 (2021).
Vader, P., Mol, E. A., Pasterkamp, G. & Schiffelers, R. M. Extracellular vesicles for drug supply. Adv. Drug Deliv. Rev. 106, 148–156 (2016).
Wiklander, O. P. B. et al. Antibody-displaying extracellular vesicles for focused most cancers remedy. Nat. Biomed. Eng. 8, 1453–1468 (2024).
Yue, Y. et al. Antigen-bearing outer membrane vesicles as tumour vaccines produced in situ by ingested genetically engineered micro organism. Nat. Biomed. Eng. 6, 898–909 (2022).
Ruhland, M. Ok. et al. Visualizing synaptic switch of tumor antigens amongst dendritic cells. Most cancers Cell 37, 786–799.e5 (2020).
Pitt, J. M. et al. Dendritic cell-derived exosomes for most cancers remedy. J. Clin. Make investments. 126, 1224–1232 (2016).
Pitt, J. M. et al. Dendritic cell-derived exosomes as immunotherapies within the combat towards most cancers. J. Immunol. 193, 1006–1011 (2014).
Mu, N. et al. Plant-derived exosome-like nanovesicles: present progress and prospects. Int. J. Nanomed. 18, 4987–5009 (2023).
Lian, M. Q. et al. Plant-derived extracellular vesicles: latest developments and present challenges on their use for biomedical purposes. J. Extracell. Vesicles 11, e12283 (2022).
Wong, A. S., Che, C. M. & Leung, Ok. W. Current advances in ginseng as most cancers therapeutics: a practical and mechanistic overview. Nat. Prod. Rep. 32, 256–272 (2015).
Liu, S. et al. Structural characterization of a novel polysaccharide from Panax notoginseng residue and its immunomodulatory exercise on bone marrow dendritic cells. Int. J. Biol. Macromol. 161, 797–809 (2020).
Kang, S. & Min, H. Ginseng, the ‘immunity enhance’: the results of panax ginseng on immune system. J. Ginseng Res. 6, 354–368 (2012).
Krawczyk, Ok. et al. Electrogenetic mobile insulin launch for real-time glycemic management in sort 1 diabetic mice. Science 368, 993–1001 (2020).
Hao, Y. et al. Promotion or inhibition of extracellular vesicle launch: rising therapeutic alternatives. J. Management. Launch 340, 136–148 (2021).
Mayer, A. Intracellular membrane fusion: SNAREs solely?. Curr. Opin. Cell Biol. 11, 447–452 (1999).
Bennaceur, Ok. et al. Dendritic cells dysfunction in tumour atmosphere. Most cancers Lett. 272, 186–196 (2008).
Feng, J. et al. Plant-derived vesicle-like nanoparticles as promising biotherapeutic instruments: current and future. Adv. Mater. 35, e2207826 (2023).
Li, Q. et al. The mixture of gemcitabine and ginsenoside Rh2 enhances the immune operate of dendritic cells towards pancreatic most cancers through the CARD9-BCL10-MALT1/NF-κB pathway. Clin Immunol. 248, 109217 (2023).
Son, Ok. J., Choi, Ok. R., Lee, S. J. & Lee, H. Immunogenic cell dying induced by ginsenoside Rg3: significance in dendritic cell-based anti-tumor immunotherapy. Immune Netw. 16, 75–84 (2016).
Zhang, Y. et al. Purposeful regulation of ginsenosides on myeloid immunosuppressive cells within the tumor microenvironment. Integr. Most cancers Ther. 18, 1534735419886655 (2019).
Kalluri, R. The biology and performance of exosomes in most cancers. J. Clin. Make investments. 126, 1208–1215 (2016).
Mathieu, M., Martin-Jaular, L., Lavieu, G. & Théry, C. Specificities of secretion and uptake of exosomes and different extracellular vesicles for cell-to-cell communication. Nat. Cell Biol. 21, 9–17 (2019).
Savina, A., Furlán, M., Vida, L. M. & Colombo, M. I. Exosome launch is regulated by a calcium-dependent mechanism in K562 cells. J. Biol. Chem. 278, 20083–20090 (2003).
Messenger, S. W., Woo, S. S., Solar, Z. & Martin, T. F. J. A Ca2+-stimulated exosome launch pathway in most cancers cells is regulated by Munc13-4. J. Cell Biol. 217, 2877–2890 (2018).
MacNabb, B. W. et al. Dendritic cells can prime anti-tumor CD8+ T cell responses by way of main histocompatibility advanced cross-dressing. Immunity 55, 2206–2208 (2022).
Pittet, M. J., Di Pilato, M., Garris, C. & Mempel, T. R. Dendritic cells as shepherds of T cell immunity in most cancers. Immunity 56, 2218–2230 (2023).
Reis e Sousa, C. Dendritic cells in a mature age. Nat. Rev. Immunol. 6, 476–483 (2006).
Moon, C. Y. et al. Dendritic cell maturation in most cancers. Nat. Rev. Most cancers 25, 225–248 (2025).
Carrillo-Conde, B. et al. Mannose-functionalized ‘pathogen-like’ polyanhydride nanoparticles goal C-type lectin receptors on dendritic cells. Mol. Pharm. 8, 1877–1886 (2011).
Tomura, M. et al. Monitoring and quantification of dendritic cell migration and antigen trafficking between the pores and skin and lymph nodes. Sci. Rep. 4, 6030 (2014).
Moriya, T. et al. Immunogenic tumor cell dying promotes dendritic cell migration and inhibits tumor progress through enhanced T cell immunity. iScience 24, 102424 (2021).
Shand, F. H. et al. Monitoring of intertissue migration reveals the origins of tumor-infiltrating monocytes. Proc. Natl Acad. Sci. USA 111, 7771–7776 (2014).
Manno, M., Bongiovanni, A., Margolis, L., Bergese, P. & Arosio, P. The physico-chemical panorama of extracellular vesicles. Nat. Rev. Bioeng. 3, 68–82 (2025).
Wang, S. et al. Macrophage-tumor chimeric exosomes accumulate in lymph node and tumor to activate the immune response and the tumor microenvironment. Sci. Transl. Med. 13, eabb6981 (2021).
Qin, H. et al. Improvement of a most cancers vaccine utilizing in vivo click-chemistry-mediated lively lymph node accumulation for improved immunotherapy. Adv. Mater. 33, e2006007 (2021).
Li, N. et al. Potent prophylactic most cancers vaccines harnessing floor antigens shared by tumour cells and induced pluripotent stem cells. Nat. Biomed. Eng. 9, 215–233 (2025).
Gong, N. et al. Enhancing in situ most cancers vaccines utilizing supply applied sciences. Nat. Rev. Drug Discov. 23, 607–625 (2024).